A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.
Also called NCT03861039
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 443 participants
- Sponsor
- Registry
-
NCT03861039
-
- Other papers using this trial's data
- Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03861039. Randomized; no masking; primary purpose treatment. Start 2019-03-30 (actual); primary completion 2021-01-26 (actual). Results posted on 2022-02-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Oral antihyperglycemic medication (OAM)
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03861039- Content hash
06fadafa7c7720d50ebf5ba1eb3d008d9b8c05eb8dacc07300aa37a590ddf00c